Use of a Behavioral Economic Intervention to Reduce Antibiotic Prescription for Upper Respiratory Infections

Sponsor
University of California, Los Angeles (Other)
Overall Status
Completed
CT.gov ID
NCT03464279
Collaborator
LAC+USC Medical Center (Other), Los Angeles County Department of Public Health (Other)
2,500
1
2
34
73.4

Study Details

Study Description

Brief Summary

In an effort to implement Choosing Wisely guidelines and decrease patient harm, we will implement and evaluate a clinician audit-feedback and behavioral "nudge" initiative to reduce low-value antibiotics for URIs. Using a quasi-experiment (pre-post) design, antibiotic prescriptions for URI at LAC+USC Urgent Care Center (intervention site) vs. Olive View-UCLA Urgent Care Center (control site) will used to test the effects of behavioral "nudge" on antibiotic prescribing.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Nudge using Behavioral Economic Interventions
  • Behavioral: Standard Practices to Reduce Health System Antibiotic Prescription
N/A

Detailed Description

National prescription rates for low-value antibiotics for uncomplicated upper respiratory infections (URIs) remain unacceptably high, including at LAC+USC Medical Center-one of the largest safety net medical centers in the U.S. Using a quasi-experiment (pre-post) design, antibiotic prescriptions for URI at LAC+USC Urgent Care Center (intervention site) vs. Olive View-UCLA Urgent Care Center (control site) will be compared. A three-part intervention at LAC+USC consists of (1) the urgent care medical director emailing Choosing Wisely® guidelines and presented journal club to all 16 urgent care clinicians, and then (2) leveraging EHR performance data to provide individual clinicians with case-specific audit-feedback (both via emails and in-person while precepting nurse practitioners) on low-value antibiotic prescribing, and (3) using a behavioral "nudge", urgent care clinicians will sign a large poster committing to avoid prescribing low-value antibiotics for uncomplicated URIs, which will be displayed in the clinic. In contrast, the control site (Urgent Care Center at Olive View-Medical Center) will receive Centers for Disease Control prescription pads for non-antibiotic treatments (e.g., decongestants) that offer patients alternatives to antibiotics, in a broader health system effort to reduce antibiotic prescribing. Patient with URIs (e.g., acute bronchitis, bronchitis NOS, excluding guideline-based red flags such as COPD, HIV) will be identified using electronic health record clinical billable data and low-value antibiotic prescriptions rates per visit will be monitored at both sites. Differences in prescriptions rates will be determined using an interrupted time-series analysis comparing utilization between sites using a repeated measures logistic regression model.

.

Study Design

Study Type:
Interventional
Actual Enrollment :
2500 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Health Services Research
Official Title:
Use of a Behavioral Economic Intervention to Reduce Antibiotic Prescription for Upper Respiratory Infections
Actual Study Start Date :
May 29, 2015
Actual Primary Completion Date :
Mar 30, 2018
Actual Study Completion Date :
Mar 30, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention Site

The intervention Site (Urgent Care Center at LAC+USC Medical Center) will receive a three part intervention consisting of (1) Email Choosing Wisely® guidelines and presented journal club to all 16 urgent care clinicians, (2) leveraging EHR performance data to provide individual clinicians with case-specific audit-feedback (both via emails and in-person while precepting nurse practitioners) on low-value antibiotic prescribing, and (3) using a behavioral "nudge", urgent care clinicians will sign a large poster committing to avoid prescribing low-value antibiotics for uncomplicated URIs displayed in the clinic.

Behavioral: Nudge using Behavioral Economic Interventions

Active Comparator: Control Site

The control site (Urgent Care Center at Olive View-Medical Center) will receive broader health system efforts to reduce antibiotic prescribing consisting of Center for Disease Control prescription pads for non-antibiotic treatments (e.g., decongestants) that offer patients alternatives to antibiotics.

Behavioral: Standard Practices to Reduce Health System Antibiotic Prescription

Outcome Measures

Primary Outcome Measures

  1. Change in Low-value antibiotic prescriptions rates per visit [1 year]

    Changes in inappropriate antibiotic prescriptions rates per visit before and after implementation of intervention at both sites

Secondary Outcome Measures

  1. Coding Shift (ie, a shift in use of diagnostic codes to conditions that are more antibiotic appropriate) in URI diagnosis [1 year]

    Change frequency of proportion of antibiotic appropriate diagnoses before intervention and after at both sites.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • all patient receiving treatment for Upper Respiratory Infections (defined by ICD codes EHR billable codes) at both LAC+USC Medical Center Urgent Care or Olive View-UCLA Medical Center
Exclusion Criteria:
  • Patients not receiving treatment for Upper Respiratory Infections at both LAC+USC Medical Center Urgent Care or Olive View-UCLA Medical Center

Contacts and Locations

Locations

Site City State Country Postal Code
1 Los Angeles County +University of Southern California (LAC+USC) Medical Center Los Angeles California United States 90033

Sponsors and Collaborators

  • University of California, Los Angeles
  • LAC+USC Medical Center
  • Los Angeles County Department of Public Health

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Catherine A. Sarkisian, Professor in Residence, University of California, Los Angeles
ClinicalTrials.gov Identifier:
NCT03464279
Other Study ID Numbers:
  • IRB #16-000932-004
First Posted:
Mar 14, 2018
Last Update Posted:
May 2, 2018
Last Verified:
Apr 1, 2018
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 2, 2018